These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15899507)

  • 41. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
    Whyte MP
    Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H; Kanatani M; Sugimoto T; Chihara K
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of Herba Epimedii flavone on the osteoblasts metabolism in vitro].
    Liu YH; Zhang HY; Zang HM; Cheng JC
    Zhongguo Zhong Yao Za Zhi; 2006 Mar; 31(6):487-90. PubMed ID: 16722381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts.
    Lamghari M; Tavares L; Camboa N; Barbosa MA
    J Cell Biochem; 2006 Aug; 98(5):1123-9. PubMed ID: 16479591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples.
    Seck T; Diel I; Bismar H; Ziegler R; Pfeilschifter J
    Eur J Endocrinol; 2001 Aug; 145(2):199-205. PubMed ID: 11454517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.
    Tada T; Jimi E; Okamoto M; Ozeki S; Okabe K
    Int J Cancer; 2005 Aug; 116(2):253-62. PubMed ID: 15800904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.
    Garlet GP; Cardoso CR; Silva TA; Ferreira BR; Avila-Campos MJ; Cunha FQ; Silva JS
    Oral Microbiol Immunol; 2006 Feb; 21(1):12-20. PubMed ID: 16390336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor.
    Zannettino AC; Holding CA; Diamond P; Atkins GJ; Kostakis P; Farrugia A; Gamble J; To LB; Findlay DM; Haynes DR
    J Cell Physiol; 2005 Aug; 204(2):714-23. PubMed ID: 15799029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts.
    Ling LJ; Ho FC; Chen YT; Holborow DW; Liu TY; Hung SL
    J Clin Periodontol; 2005 Apr; 32(4):353-9. PubMed ID: 15811051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
    Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
    Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification.
    Al-Fakhri N; Hofbauer LC; Preissner KT; Franke FE; Schoppet M
    Thromb Haemost; 2005 Dec; 94(6):1335-7. PubMed ID: 16411417
    [No Abstract]   [Full Text] [Related]  

  • 56. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin.
    Nagasawa T; Kobayashi H; Kiji M; Aramaki M; Mahanonda R; Kojima T; Murakami Y; Saito M; Morotome Y; Ishikawa I
    Clin Exp Immunol; 2002 Nov; 130(2):338-44. PubMed ID: 12390325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
    Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
    Blair JM; Zhou H; Seibel MJ; Dunstan CR
    Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The molecule mechanism of soybean isoflavaones antagonizing bone loss induced by postmenopausal osteoporosis].
    Wang Q; Wang K; Wang X
    Zhong Yao Cai; 2005 Oct; 28(10):910-3. PubMed ID: 16479929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.